Structure Therapeutics completes phase 2 body composition trial of oral aleniglipron
The 44-week randomized study assigned adults with BMI of 30 or higher to aleniglipron or placebo in a 5:1 ratio with four-week titration steps.
PR
By Priya Raman · Science Reporter
Oct 14 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT07169942, sponsored by Structure Therapeutics subsidiary Gasherbrum Bio, is listed as completed; it tested oral GLP-1 agonist aleniglipron (GSBR-1290) on body composition in obesity, starting August 2025.
- 02Body composition data address the lean-mass question dogging incretin therapy, and an oral small-molecule option would change supply and compounding dynamics.
- 03The registry entry carries no results; the design is placebo-controlled with multiple ascending once-daily doses over 44 weeks.
From the source
Read at clinicaltrials.govAleniglipron Phase 2 Body Composition Study
NCT07169942 · PHASE2 · COMPLETED · Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Conditions: Obesity, Overweight, or Chronic Weight Management.
Source URL https://clinicaltrials.gov/study/NCT07169942
